PMV Pharmaceuticals

PMV Pharmaceuticals' mission is to conquer cancer by correcting the function of mutant p53, the most frequently altered tumor suppressor in human oncology. The company's core achievement is advancing rezatapopt (PC14586), a first-in-class p53 Y220C reactivator, into the pivotal PYNNACLE Phase 1/2 study, with data recently published in the New England Journal of Medicine demonstrating proof-of-concept. Its strategy integrates a mutation-focused, tumor-agnostic development path with a deep pipeline targeting additional p53 hotspot mutations, aiming to establish a new class of precision oncology therapeutics. PMV operates as a publicly traded entity, building upon over four decades of foundational p53 research co-discovered by its scientific founder.

A proprietary platform integrating structural biology, computational modeling, and medicinal chemistry to discover small molecules that selectively bind to and stabilize specific, druggable mutant p53 proteins, restoring their wild-type tumor suppressor function.

PMV is a clear leader in direct p53 reactivation, with no competitor having advanced a selective compound as far clinically. The landscape consists of a few early-stage academic efforts and previous non-selective stabilizers that faced clinical setbacks, giving PMV a significant first-mover advantage if successful.